USFDA Approval Granted for manufacturing and marketing Fenofibrate Capsules To Ranbaxy Laboratories Ltd.

US FDA has granted approval to Ranbaxy Laboratories Ltd for manufacture and marketing of Fenofibrate USP 43 and 130 mg. The product will be manufactured at Ranbaxy's Ohm Laboratories situated New Brunswick, New Jersey and will be launched thereafter.

Fenofibrate capsules are used for lowering high cholesterol and triglycerides in the blood.These capsules are intented for primary hypercholesterolemia and mixed dyslipidemia. In addition, it is indicated for severe hypertriglyceridemia.